Expertise in
32
conditions

Dr. John F. Dipersio

Hematology
Washington University
4500 Forest Park Ave, 
Saint Louis, MO 
Accepting New Patients
45 Years of Experience
Expertise in
32
conditions
Washington University
4500 Forest Park Ave, 
Saint Louis, MO 

Overview

John Dipersio is a Hematologist practicing medicine in Saint Louis, Missouri. He has been practicing medicine for over 45 years.

Dr. Dipersio is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 321 peer reviewed articles and participating in 41 clinical trials. Dr. Dipersio is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Christian Hospital Northeast

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Washington University
4500 Forest Park Ave, Saint Louis, MO 63108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

41 Clinical Trials

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Enrollment Status: Suspended
Publish Date: July 21, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2026
Intervention Type: Procedure, Drug
Study Drugs: Tacrolimus, Mycophenolate mofetil, G-CSF, ALT-803
Study Phase: Phase 2
A Pilot Study Evaluating the Safety and Efficacy of Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
A Pilot Study Evaluating the Safety and Efficacy of Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Enrollment Status: Terminated
Publish Date: May 06, 2026
Intervention Type: Drug, Procedure
Study Drug: Duvelisib
Study Phase: Phase 2
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Procedure, Drug
Study Drug: CIML NK Cell Infusion
Study Phase: Phase 1/Phase 2
A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Belimumab
Study Phase: Phase 1
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 16, 2026
Intervention Type: Procedure
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Procedure
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Procedure
Study Drugs: Anti-thymocyte globulin, Solumedrol, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 1
View 9 Less Clinical Trials

321 Total Publications

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.
Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.
Journal: NEJM evidence
Published: August 25, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Brad S. Kahl
Hematology
Expertise in
28
conditions
Dr. Brad S. Kahl
Hematology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.7 miles away)
314-747-1171
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Kahl is a Hematologist practicing medicine in Saint Louis, Missouri. Dr. Kahl is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kahl is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.7 miles away)
314-747-1171
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neha Mehta-Shah is a Hematologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 17 years. Dr. Mehta-Shah is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mehta-Shah is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (0.1 miles away)
314-454-8304
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geoffrey Uy is a Hematologist practicing medicine in Saint Louis, Missouri. Dr. Uy is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Uy is currently accepting new patients.

Frequently Asked Questions about Dr. John F. Dipersio

How do I make an appointment with Dr. John F. Dipersio?

You can book an appointment with Dr. John F. Dipersio by calling their office at 314-454-8304. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John F. Dipersio a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John F. Dipersio is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John F. Dipersio specialize in?

While Dr. John F. Dipersio is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John F. Dipersio participate in research or clinical trials?

Yes. Dr. John F. Dipersio has published 321 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. John F. Dipersio's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John F. Dipersio accept my insurance?

Dr. John F. Dipersio accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-454-8304 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dipersio's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 21 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile